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Abstract
Background: Radical cystectomy (RC) still poses a significant 
risk for mortality and morbidity. Objectives: We compared 
in-hospital outcomes after RC in the United States and 
 Germany using population-based data. Methods: We com-
pared data from the US Nationwide Inpatient Sample to the 
German hospital billing database. Mortality and transfusion 
during hospital stay and length of stay (LOS) were evaluated. 
Results: In all, 17,711 (the United States) and 60,447 ( Germany) 
cases were included. The share of robot-assisted RC increased 
to 20.5% in the United States vs. 2.3% in Germany (p < 0.001). 
In-hospital mortality was 1.9% (the United States) vs. 4.6% 
(Germany), transfusion rates were 34.2% (the United States) 
vs. 58.7% (Germany), and LOS was 10.7 (the United States) vs. 
25.1 days (Germany; all p < 0.001). On multivariate analysis, 
higher patient age and lower annual hospital caseload were 
associated with increased mortality and longer LOS. Minimal-
invasive surgery was associated with less blood transfusion 
and shorter LOS in the United States vs. hospital caseload and 
choice of urinary diversion in Germany. Conclusions: Health-
care systems might exert a relevant impact on outcomes of 
oncologic surgery. Increased in-hospital mortality rates in 
Germany seem to be partly explained by much longer LOS 
compared to those in the United States. Annual caseload 
seems to be influential on in-hospital outcomes raising the 
question of centralization of RC. © 2019 S. Karger AG, Basel
Introduction
With a yearly incidence of 77,000 in the United States 
and 30,000 in Germany, bladder cancer poses a major 
burden on the population [1, 2]. For patients with mus-
cle-invasive or superficial treatment-refractory cancer 
radical cystectomy (RC) remains the gold standard. The 
morbidity and mortality are among the highest in onco-
logical surgery [3–7]. Influential factors are the high level 
of invasiveness combined with patient-derived factors 
such as the elevated mean patient’s age and greater co-
morbidity [4, 6, 8, 9]. 
Improvements in perioperative care, anesthesia, and 
surgical technique have led to a decrease in postoperative 
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mortality with rates from 20% in the late 1970s to cur-
rently between 2.5 and 7.9% [3, 5]. Higher surgical vol-
ume is associated with improved outcomes [7, 10–13], 
but the magnitude of this effect remains controversial. 
While several studies emphasize the importance of the 
surgeon’s experience [7], the influence of treating institu-
tion and perioperative management might be additional 
key factors to reduce in-hospital morbidity and mortality 
[10, 11, 13]. The introduction of laparoscopic RC (LRC) 
and later robot-assisted RC (RARC) has achieved less 
blood loss, wound infections, and a shorter length of hos-
pital stay (LOS) compared to open RC (ORC) in several 
single-center studies [5, 14]. However, a randomized con-
trolled trial failed to identify a large advantage for RARC 
[15].
The United States and Germany entertain very di-
versely developed and organized health care systems [16]. 
To this day, no studies about outcomes of RC in Germany 
exist on a total population level and there are no studies 
comparing RC outcomes between large western health-
care systems.
The aim of the study is to fill this gap and to compare 
recent trends of in-hospital mortality, blood transfu-
sion  rates, and LOS after RC in the United States and 
 Germany.
Materials and Methods
US Nationwide Inpatient Sample
To obtain data of RCs in the United States, we utilized the Na-
tionwide Inpatient Sample (NIS) covering the years 2006–2014 
provided by the Healthcare Cost and Utilization Project. The NIS 
comprises a representative 20% sample of all hospital admissions 
in the United States. The relevant patient cohort was identified 
similar to our previously described method [17]. Inclusion criteria 
were the diagnosis of a bladder neoplasm in combination with a 
coded procedure of RC and a minimum age of 18 at surgery. Anal-
yses involving hospital caseload are restricted to the years 2006–
2011.
German Billing Database
The German Federal Statistical Office entertains a nationwide 
billing database. For the purpose of this study the data is virtually 
complete. Cohort identification and data extraction were per-
formed accordingly and similarly to previously described methods 
[11].
Please refer to the online supplement for further details.
Statistics
We extracted the absolute number of cases and calculated 
rates for mortality and blood transfusion. Results were stratified 
for age, gender, type of urinary diversion (UD), surgical ap-
proach, and annual hospital caseload. We applied linear models 
for LOS, and logistic models for in-hospital mortality and blood 
transfusion. To detect trends over time, linear regression was im-
plemented. We compared rates, means and trends using Wald-
tests. A value level of p < 0.05 was regarded as significant. We 
used SAS 9.4 (SAS Institute GmbH, Heidelberg, Germany) for all 
analyses. 
Results
Seventeen thousand seven hundred and eleven cases 
from the NIS database were included with a varying an-
nual total caseload between 1,666 in 2006 and 2,009 in 
2014. From the German billing database 60,447 cases of 
RC with bladder cancer were extracted. Annual caseload 
increased continuously from 5,627 in 2006 to 7,390 in 
2014. Patient characteristics and patterns of care are pre-
sented in Table 1. The mean age of patients in the United 
States remained stable at 68.2 ± 10.5 (p = 0.9) years while 
increasing in Germany from 68.0 ± 9.6 to 69.4 ± 9.9 (p < 
0.001) years (p < 0.001 for trend comparison). 
Caseload Distribution (2006–2011)
Figure 1 gives an overview of the caseload distribution. 
The majority of US hospitals served low annual casel-
oads <4 cases with a decreasing respective share of pa-
tients from 16.5 to 10.5% (p = 0.019) and an increasing 
share for high volume hospitals (> 50 cases) from 4.1 to 
41.5% (p = 0.004). In Germany, the shares of RC in low 
and high volume hospitals remained stable at 0.9% (p = 
0.9) and 14.1% respectively (p = 0.2). 
Figure 2 demonstrates the development of surgical ap-
proaches in both countries. The share of LRC remained 
stable in the United States (p = 0.6) while increasing for 
RARC from 0.7 to 20.5% (p < 0.001), and decreasing for 
ORC from 99.7 to 79.1% (p < 0.001). In Germany, LRC 
increased from 0.7 to 1.5% (p < 0.001) and RARC from 0 
to 2.3% (p < 0.001), while ORC decreased from 99.3 to 
96.2% (p < 0.001). 
In-Hospital Mortality
In-hospital mortality was 1.9% in the United States vs. 
4.6% in Germany (p < 0.001). Mortality rates differed for 
different surgical approaches in the United States (LRC 
1.6% vs. RARC 1.1% vs. ORC 2.0%; p  = 0.003) and 
 Germany (LRC 3.4% vs. RARC 2.4% vs. ORC 4.6%; p < 
0.001). Higher annual caseloads were associated with 
lower mortality in the United States (< 4 cases 3.6% vs. 
4–10 cases 2.4% vs. 11–25 cases 2.6% vs. 26–50 cases 1.2% 
vs. >50 cases 1.5%; p < 0.001) and Germany (< 4 cases 6.7% 
Groeben/Koch/Baunacke/Borkowetz/
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vs. 4–10 cases 5.0% vs. 11–25 cases 5.0% vs. 26–50 cases 
4.1% vs. >50 cases 3.3%; p = 0.002).
On multivariate analysis (Table 2) in the United States 
increasing age and lower annual hospital caseload were 
the most important risk factors for in-hospital mortality. 
In Germany, increasing age, lower annual hospital casel-
oad, and the type of UD had the highest impact. 
Blood Transfusion
The overall rate of blood transfusion in the United 
States was 34.2 vs. 58.7% in Germany (p < 0.001) with a 
significant decrease in Germany from 61.1 to 52.4% (p = 
0.002). The transfusion rate concerning surgical approach 
in the United States was 38.1% for LRC, 23.3% for RARC 
and 35.9% for ORC (p = 0.012). In Germany, transfusion 
rates were 48.4% for LRC, 33.6% for RARC and 59.2% for 
ORC (p < 0.001). Low annual caseloads were also associ-
ated with higher rates of blood transfusion in the United 
States (< 4 cases 42.1% vs. 4–10 cases 35.6% vs. 11–25 cases 
35.7% vs. 26–50 cases 31.4% vs. > 50 cases 36.5%; p < 0.001) 
and Germany (< 4 cases 63.2% vs. 4–10 cases 64.0% vs. 11–
25 cases 59.7% vs. 26–50 cases 58.9% vs. > 50 cases 51.4%; 
p < 0.001).
Multivariate analysis (Table 2) indicated open surgery 
followed by female gender and hospital size to be the most 
influential factors for blood transfusion in the United 
States, while in Germany, this were female gender fol-
lowed by higher age. Open surgery, choice of UD, and low 
hospital caseload were additional relevant covariates.
Length of Stay
The overall LOS for RC decreased in the United States 
from 11.3 ± 8.1 to 9.7 ± 7.4 days (p < 0.001) and in Germany 
from 26.8 ± 14.6 to 24.2 ± 15.4 days (p < 0.001; p = 0.084 for 
comparison of trends). In the United States, LOS was longer 
for LRC with 12.3 ± 13.5 vs. 8.7 ± 5.7 (RARC) and 10.9 ± 8.8 
days for ORC (p = 0.004). In Germany, LRC also entailed 
the longest LOS with 25.4 ± 21.5 vs. 21.5 ± 12.7 (RARC) and 
ORC with 25.2 ± 14.6 days (p < 0.001). High-volume hos-
pitals presented shorter LOS in the United States (< 4 cases 
11.4 ± 8.8 vs. 4–10 cases 10.8 ± 8.1 vs. 11–25 cases 10.8 ± 9.1 
vs. 26–50 cases 9.8 ± 7.1 vs. > 50 cases 10.3 ± 9.2 days p < 
0.001) and in Germany (< 4 cases 24.5 ± 12.1 vs. 4–10 cases 
26.3 ± 15.6 vs. 11–25 cases 26.1 ± 14.6 vs. 26–50 cases 24.7 ± 
14.4 vs. >50 cases 23.3 ± 13.8 days; p = 0.036).
Multivariate analysis (Table 3) of the US data indicated 
hospital caseload to be the most important factor for LOS 
followed by surgical approach, age of patients, and choice 
of UD. In Germany surgical approach had no significant 
influence, while choice of UD and hospital caseload had 
a high impact. Teaching status, gender, and age were fac-
tors that were less influential.
Table 1. Patient characteristics and patterns of care of RC in the United States and Germany (years 2006–2011)
United States Germany p value
Total number of patients, n 11,837 38,516
Gender, n (%)
Male 9,038 (76.4) 28,817 (74.8) 0.0007
Age, years, mean ± SD 68.2±10.5 68.8±9.9 <0.0001
Annual hospital caseload, n (%)
0–3 1,508 (12.7) 381 (1.0) <0.0001
4–10 2,733 (23.1) 3,868(10.0)
11–25 2,676 (22.6) 16,217 (42.1)
26–50 1,776 (15.0) 12,837 (33.3)
>50 3,144 (26.6) 5,231 (13.6)
Teaching status, n (%)
Academic 8,846 (74.7) 7,444 (19.3) <0.0001
Size of hospital, n (%)
Small 1,070 (9.0) 6,058 (15.7) <0.0001
Medium 1,897 (16.0) 17,838 (46.3)
Large 8,870 (75.0) 14,620 (38.0)
Hospital location, n (%)
Urban 11,452 (96.7) 34,105 (88.5) <0.0001
Rural 385 (3.3) 4,411 (11.5)
RC, radical cystectomy.
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Discussion
In-hospital mortality, blood transfusion rates, and the 
LOS were considerably lower in the United States than 
in Germany. Multivariate models indicated patient age 
and annual hospital caseload to be important factors for 
mortality and LOS in both countries. In the United 
States, surgical approach had a significant influence on 
transfusion and the LOS, while in Germany, most influ-
ential factors were hospital caseload and the choice of 
UD. 
RARC is a well-established alternative to ORC in the 
United States with constantly inclining numbers while 
the magnitude of this trend is not seen in Germany. This 
development is in line with the slower implementation of 
robot-assisted surgery for other indications in Germany 
[18, 19]. This might be due to the lack of additional reim-
bursement for the use of a surgical robot due to the prin-
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ciple of cost containment in German healthcare policy 
[16, 17]. A growing body of evidence shows advantages of 
RARC concerning decreased blood loss and wound infec-
tions and shorter LOS [5, 14]. This is confirmed by our 
multivariate models. In univariate analysis, in-hospital 
mortality rates were also lower after RARC in both coun-
tries. Obviously, clinical case selection might explain 
these differences. 
In-hospital mortality in the United States was less than 
half of the German rate (2.2 vs. 4.6%). This difference is 
largely explained by the shorter time of observation, since 
LOS in the United States was also less than half that in 
Germany (10.7 vs. 25.2 days). When comparing current 
30- or 90-day mortality rates from the literature, the dif-
ference between the 2 countries appears negligible [3, 7, 
13]. Additionally, the mean age of RC patients in Ger-
many is higher and constantly inclining in Germany [4, 
6], while older age proved to be the most important risk 
factor for in-hospital mortality in both countries followed 
by annual caseload. In Germany, incontinent UD also 
showed significant influence. The missing influence for 
the US data might not be seen due to higher rates of in-
continent UD (USA 93 vs. 71% Germany in 2014). Since 
almost every patient received incontinent UD in the 
United States, the clinical selection of older and frailer 
patients is likely to be masked [17]. Although these results 
imply a careful selection of older patients for RC, current 
studies showed acceptable rates of complications and 
mortality when older patients were treated in surgical 
centers [9].
Age, sex, and minimal invasive RC were influential 
factors for blood transfusion in both countries. Thus, ex-
planations for the significant difference in transfusion 
rates must be seen in higher average age, a greater share 
of female patients, and much lower use of RARC in 
 Germany. Additionally, we assume differences in clinical 
practice, although this is not supported by respective na-
tional guidelines [20, 21]. Despite declining transfusion 
rates in Germany, more restrictive regimens might be re-
quired.
Older age and lower annual caseload increased the 
LOS in both countries, which is in line with existing lit-
erature [6]. Fundamental differences in concepts of peri-
operative care must be taken into account when assessing 
the marked difference in LOS between the United States 
and Germany. The German healthcare system is publicly 
financed with legal obligation to health care insurance 
and almost universal coverage of health care expenses. 
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Ambulatory and stationary care is reimbursed by either 
statutory or privately financed sickness funds. The statu-
tory sickness funds are nonprofit organizations and the 
respective contributions by the insured are linked to the 
annual income. Roughly 10.5% of German citizens are 
insured through privately financed sickness funds. Fed-
eral, state, and communal governments exert fundamen-
tal influence on German health care. For example, health 
care legislation happens on a federal level, a significant 
share of hospitals is state or communally owned, and the 
government supervises the sickness funds and the physi-
cian associations. 
The US health care system, on the other hand, is less 
government-regulated and relies more on the concept of 
the private market. The majority of citizens are privately 
insured and about one fourth relies on public insurance. 
Full access to health care for every citizen independent of 
income is available only since 2010 with the Affordable 
Care Act. The reimbursement of the health care providers 
is accomplished mainly by commercial health care pro-
viders and to a minor share by federal and state govern-
ments on the other hand. Therefore, the financial risk 
generated by perioperative complications or prolonged 
hospital stays is distributed differently in both countries. 
Most German patients do not have to cover any of these 
costs. However, a relevant share of US patients does, thus 
making perioperative cost containment an even more de-
sirable goal in the US healthcare system [16, 22]. Addi-
tionally, US healthcare providers themselves are respon-
sible to be cost-efficient leading to reduced postoperative 
Table 2. Logistic models of the prognostic factors for the probability of mortality or blood transfusion during the hospital stay following 
RC in Germany and the United States of the years 2006–2011
Variable United States Germany
mortality transfusion mortality transfusion
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Individual surgery performed as laparoscopy or robot-assisted
No 1.44 (0.74–2.83) 0.2854 1.70 (1.43–2.03) <0.0001 0.89 (0.60–1.31) 0.5430 1.97 (1.76–2.20) <0.0001
Yes (reference) 1 – 1 – 1 – 1 –
Urinary diversion
Incontinent 1.40 (0.71–2.76) 0.3374 1.02 (0.88–1.23) 0.8075 2.04 (1.78–2.34) <0.0001 1.61 (1.55–1.68) <0.0001
Continent (reference) 1 – 1 – 1 – 1 –
Annual hospital caseload
0–3 2.26 (1.41–3.62) 0.0007 1.15 (0.99–1.33) 0.0704 2.16 (1.37–3.40) 0.0010 1.62 (1.34–1.95) <0.0001
4–10 1.51 (1.00–2.28) 0.0482 0.92 (0.81–1.03) 0.1418 1.53 (1.20–1.94) 0.0005 1.48 (1.37–1.60) <0.0001
11–25 1.58 (1.08–2.31) 0.0188 0.97 (0.87–1.08) 0.5374 1.22 (1.22–1.81) <0.0001 1.28 (1.20–1.36) <0.0001
26–50 0.78 (0.47–1.30) 0.3374 0.82 (0.72–0.93) 0.0021 1.03 (1.03–1.50) 0.0253 1.02 (0.97–1.08) 0.8091
50+ (reference) 1 – 1 – 1 – 1 –
Teaching Status
Non-academic 0.95 (0.69–1.31) 0.7445 0.96 (0.87–1.07) 0.4627 1.05 (0.88–1.24) 0.5969 1.36 (1.27–1.41) <0.0001
Academic(reference) 1 – 1 – 1 – 1 –
Size of the hospital
Small 0.59 (0.36–0.99) 0.0457 1.49 (1.31–1.69) <0.0001 0.93 (0.78–1.12) 0.4582 0.75 (0.70–0.79) <0.0001
Medium 1.09 (0.80–1.51) 0.5792 1.19 (1.07–1.32) 0.0016 1.14 (0.99–1.31) 0.6721 0.90 (0.86–0.94) 0.0159
Large (reference) 1 – 1 – 1 – 1 –
Gender
Female 1.07 (0.81–1.41) 0.6367 1.63 (1.49–1.78) <0.0001 0.81 (0.72–0.91) 0.0003 2.34 (2.25–2.45) <0.0001
Male (reference) 1 – 1 – 1 – 1 –
Age
>50 (reference) 1 – 1 – 1 – 1 –
50–59 0.78 (0.34–1.80) 0.5644 0.90 (0.74–1.10) 0.3038 1.08 (0.71–1.66) 0.7155 1.05 (0.96–1.15) 0.3182
60–69 0.88 (0.41–1.89) 0.7456 1.08 (0.90–1.29) 0.4324 1.71 (1.15–2.54) 0.0078 1.25 (1.14–1.36) <0.0001
70–79 2.20 (1.07–4.55) 0.0330 1.27 (1.06–1.53) 0.0089 2.35 (1.59–3.47) <0.0001 1.48 (1.35–1.61) <0.0001
80+ 3.01 (1.43–6.34) 0.0037 1.42 (1.17–1.73) 0.0005 3.56 (2.38–5.32) <0.0001 2.10 (1.90–2.32) <0.0001
Statistical significant values are displayed in bold writing. RC, radical cystectomy.
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LOS [16, 23], while German hospitals are fined with fi-
nancial discounts if the LOS is below the lower limit of 
6 days [24]. Subsequently, timely postoperative discharge 
and continuous ambulatory care are enforced stronger in 
the US healthcare system [25], while German hospitals 
are more likely to monitor patients in an inpatient setting 
until autonomous provision is guaranteed.
A recent study on SEER-Medicare linked data from 
2002 to 2011 reported that only approximately 20% of 
patients with muscle-invasive bladder cancer in the Unit-
ed States underwent RC [26]. While 30% received radia-
tion or radio-chemotherapy, 50% were left without cura-
tive treatment. Although no comparable study data for 
Germany exists, we can approximate that the total num-
ber of RC for bladder cancer in 2011 (n = 6,928) account 
for 86% of the total incidence of stage ≥ T1 bladder cancer 
cases in Germany [1]. Therefore, an estimated 70–80% of 
eligible patients might have undergone RC in Germany 
in 2011 leaving a small percentage of patients for nonsur-
gical or missing curative treatment. Comparable differ-
ences in the utilization of radiotherapy in the United 
States and Germany were currently reported for treat-
ment of prostate cancer [27]. Lower implementation rates 
of RC in the United States might imply enforced positive 
patient selection with younger and healthier patients for 
surgery. This might pose a relevant explanation for lower 
mortality and transfusion rates and reduced LOS in the 
United States [4, 6]. 
Table 3. Linear models of the prognostic factors for the LOS after RC in the United States and Germany with differences (in days) com-
pared to the respective reference (years 2006–2011; SE)
Mean length of hospital stay United States Germany
10.7±8.6 days 25.1±14.7 days
Variable Difference, 
days
SE p value Difference, 
days
SE p value
Individual surgery performed as laparoscopy or robot-assisted
No +1.74 0.35 <0.0001 –0.53 0.54 0.3273
Yes (reference) 0 – – 0 – –
Urinary diversion
Incontinent +0.65 0.32 0.040 –3.08 0.17 <0.0001
Continent (reference) 0 – – 0 – –
Annual hospital caseload
0–3 +2.35 0.33 <0.0001 +1.53 0.78 0.4994
4–10 +1.12 0.26 <0.0001 +2.97 0.34 <0.0001
11–25 1.23 0.24 <0.0001 +2.31 0.26 <0.0001
26–50 –0.13 0.27 0.6295 +1.03 0.25 <0.0001
50+ (reference) 0 – – 0 – –
Teaching status
Non–academic –1.04 0.23 <0.0001 +1.58 0.23 <0.0001
Academic (reference) 0 – – 0 – –
Size of the hospital
Small –0.63 0.29 0.0234 –0.98 0.26 0.0020
Medium –0.35 0.23 0.1309 –0.42 0.20 0.0409
Large (reference) 0 – – 0 – –
Gender
Female +0.43 0.19 0.0230 +0.96 0.17 <0.0001
Male (reference) 0 – – 0 – –
Age
>50 (reference) 0 – – 0 – –
50–59 –0.47 0.41 0.2547 +0.74 0.40 0.0660
60–69 –0.20 0.39 0.6023 +1.75 0.38 <0.0001
70–79 +0.85 0.39 0.0282 +2.16 0.38 <0.0001
80+ +1.65 0.42 <0.0001 +2.85 0.42 <0.0001
Statistical significant values are displayed in bold writing. RC, radical cystectomy; LOS, length of stay.
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There is growing evidence for the positive impact of 
higher caseload volumes and surgical experience on 
postoperative outcomes following complex oncologic 
surgery [10–13], which is mirrored by our findings on 
multivariate analysis. Centralizing complex oncologic 
surgery has been repeatedly discussed [28] and recom-
mended in international guidelines [29, 30]. Some re-
gions started this process with promising results [12, 28, 
31]. In the United States, the relatively high share of RC 
in low-volume hospitals slightly decreased while increas-
ing by roughly tenfold in high-volume hospitals until 
2011, demonstrating a trend toward centralization of RC. 
Respective tendencies in Germany were not statistically 
significant although the share of RC in low-volume hos-
pitals (< 4 cases annually) was constantly below 1% dur-
ing that time. 
To our knowledge, this is the first study comparatively 
analyzing current trends of in-hospital outcomes after RC 
in the United States and Germany using population based 
data from a period of 9 years. We demonstrated, that vast 
divergences concerning in-hospital outcomes in both 
countries. A relevant share of the causes for this observa-
tion might consist in major differences of both national 
healthcare systems.
The primary limitation of our study consists in the 
lack of clinical information representing a possible 
source of bias. Also, histological parameters of the tu-
mor are not included, which makes it impossible to 
stratify the outcomes for tumor staging or grading. Al-
though billing data is highly accurate, it relies on correct 
coding by the hospital. Identification of patients or sin-
gle hospitals is prohibited due to anonymization-regu-
lations. Additional hospital stays of the same patient are 
not assignable and outcomes can be determined only for 
the inpatient stay. In the NIS coding system, hospital 
size and location are categorized by a complex algo-
rithm, which is not transferable to the German situation, 
but we applied a comparable classification mechanism. 
We anticipated known differences in content or coding 
properties relevant to our analysis and adjusted the sta-
tistical assessment accordingly. In view of the large 
number of cases, our main results should nevertheless 
be very robust.
Conclusion
High annual RC caseload was associated with reduced 
mortality and LOS in the United States and Germany. 
Mortality and transfusion rates in the United States are 
significantly lower. A much shorter LOS, stronger patient 
selection, and higher adoption of RARC in the United 
States might explain these differences to some extent. 
Shorter LOS in the United States following RC might in-
dicate possibilities to enhance cost-effectiveness and sur-
gical frequency in Germany. A trend of centralization for 
RC was only seen for the United States during the study 
period.
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